You'll receive quarterly updates on our progress.
In February, 2021, we closed an oversubscribed Series A led by Lumira Ventures. Read more about this funding round.
CEO Dr. Michael J. Cooke's and Chief Science Officer Dr. Molly Shoichet were featured in the Globe and Mail.
In July 2020, AmacaThera received approval from Health Canada for AMT-143 to proceed into Phase I clinical trials. Learn about our technology.
